UUniversal Diagnostics
Universal Diagnostics (Universal DX) is a Spanish in-vitro diagnostics company developing minimally invasive, blood-based liquid biopsy tests for early cancer detection using multi-omics, next-generation sequencing, bioinformatics and machine learning. Its lead product, Signal-C, is a blood test for colorectal cancer and advanced adenomas that has entered a US pivotal clinical trial targeting 15,000+ participants for FDA approval, backed by a commercialization deal with Quest Diagnostics. Founded in 2012 with roots in Singularity University, it is HQ'd in Madrid with sites in Seville, Ljubljana (Slovenia) and Dallas/Texas, has raised well over $100M, and in 2026 closed a ~€62M Series C in which Spain's state tech fund SETT invested €30M.
Founders
Global models 5
G
F
G
DIn the same niche 48 others
See all in the Start-ups Map →
Notes: Most funded first
Investors 8
Open as list →
E
C
E
U
O
SFunding rounds 5
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-01-20 | Series C (estimated) | €62M |
Lead not disclosed
+1 more
|
| 2025-02-27 | Venture Debt | €20M | European Investment Bank |
| 2023-11-20 | Series B | approximately $70M |
Lead not disclosed
+3 more
|
| 2021-01-14 | Series A (estimated) | €14M |
Lead not disclosed
+1 more
|
| 2018-02-05 | Series A (estimated) | €7M | Lead unknown |